Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings

16 hours ago 3

Jonathan Ponciano, The Motley Fool

Fri, March 13, 2026 astatine 8:43 AM CDT 4 min read

On February 17, 2026, Driehaus Capital Management disclosed a bargain of 432,510 shares of Praxis Precision Medicines (NASDAQ:PRAX), an estimated $80.54 cardinal commercialized based connected quarterly mean pricing.

According to an SEC filing dated February 17, 2026, Driehaus Capital Management accrued its presumption successful Praxis Precision Medicines by 432,510 shares. The estimated transaction worth is $80.54 million, based connected the mean closing terms for the 4th ended December 31, 2025. The quarter-end worth of the PRAX involvement roseate by $248.48 million, a fig reflecting some the stock acquisition and banal terms appreciation.

This was a buy, bringing the PRAX presumption to 1.87% of Driehaus's 13F assets nether management
Top holdings aft the filing:
- NYSE:TSM: $657.49 cardinal (4.5% of AUM)
- NASDAQ:CRNX: $297.35 cardinal (2.0% of AUM)
- NASDAQ: PRAX: $275.01 cardinal (1.9% of AUM)
- NASDAQ:GH: $218.91 cardinal (1.5% of AUM)
- NASDAQ:XENE: $203.42 cardinal (1.4% of AUM)
As of Thursday, shares of PRAX were priced astatine $303.37, up a staggering 685% implicit the past twelvemonth and vastly outperforming the S&P 500’s astir 19% summation successful the aforesaid period.

Metric

Value

Price (as of Friday)	$303.37
Market Capitalization	$8.4 billion
Net Income (TTM)	($303.3 million)

Praxis develops clinical-stage therapies for cardinal tense strategy disorders, including pb candidates PRAX-114 for slump and PRAX-944 for indispensable tremor.
The steadfast operates a research-driven biopharmaceutical concern exemplary with aggregate licensing agreements and probe collaborations.
It targets healthcare providers, researchers, and patients affected by neurological and psychiatric conditions.

Praxis Precision Medicines, Inc. is simply a biotechnology institution focused connected advancing therapies for cardinal tense strategy disorders characterized by neuronal imbalance. The institution leverages a robust objective pipeline and collaborations with manufacture partners to code unmet aesculapian needs successful neurology and psychiatry. Its strategical accent connected probe innovation and targeted cause improvement positions it arsenic a differentiated subordinate successful the CNS therapeutics market.

Praxis Precision Medicines is approaching aggregate imaginable regulatory milestones, and investors person surely taken notice. The institution precocious submitted 2 caller cause applications to the FDA, including ulixacaltamide for indispensable tremor and relutrigine for uncommon developmental epilepsies. If approved, those programs could propulsion Praxis from a improvement signifier biotech into a commercialized neuroscience company, thereby opening the doorway to meaningful gross for the archetypal time.

In a connection past month, CEO Marcio Souza said the steadfast believes its 4 late-stage programs crossed tremor disorders, epilepsy, and uncommon familial neurological diseases unneurotic transportation imaginable gross exceeding $20 cardinal if successfully commercialized.

Financially, the institution appears positioned to prosecute that strategy aggressively. Praxis finished 2025 with astir $926 cardinal successful currency and investments and raised an further $621 cardinal aboriginal successful January, giving it backing visibility into 2028 arsenic it advances objective trials and prepares imaginable launches.

After specified a staggering run, the accidental is clear, but truthful is the hazard if the steadfast runs into immoderate regulatory hurdles.

Read Entire Article